tbuckley/cabot-search huggingface dataset:
Abstract 1796: p53 regulation of osteoblast differentiation is mediated through specific microRNAs
Authors: Elisha Pendleton, Shivang Shah, Oliver Couture, Teresa Kusper, Mustafa Broachwalla, Lauren Alt, Michael Fay, Nalini Chandar
Journal: Cancer Research (2019)

Abstract We have previously shown a role for tumor suppressor gene p53 in the transcriptional activation of several bone-specific genes in osteoblast differentiation. In this study, we used a screen for microRNAs to look for ones that were p53 dependent and differentiation dependent. In a model of invitro osteoblast differentiation, our previous work has established that p53 levels generally increase around day 4 of differentiation and represent the timeline when p53 transcriptionally regulates bone-specific gene expression. In these experiments, we used MC3T3-E1 osteoblasts to stably reduced p53 levels using specific shRNAs. These cells were initially characterized for the reduction in p53 levels and then compared with MC3T3E1 cells stably transfected with a scrambled control (Control MC3T3E1 cells). MicroRNAs were isolated from day 0 and day 4 after treatment with differentiation promoting (DP) media. A microRNA profiling service utilizing a microarray detection system analyzed over 1000 different microRNAs in control and DP treated cells to determine differentiation specific microRNAs expression. This array provided us with information about a number of genes that underwent alterations during differentiation in a p53 dependent manner. We validated several of the changes using realtime PCR and selected two microRNAs to study in detail. These two microRNAs (mIR 34b and 140) were increased two fold during normal differentiation but showed a dramatic reduction in expression when p53 levels were reduced. We ectopically expressed these microRNAs in MC3T3-E1 cells and created stable lines. Cells carrying mIR34b showed a decrease in cell proliferation rates when compared to mIR140 expressing and control cells. P53 levels directly correlated with microRNA 34b expression but not mIR140. MiR 140 ectopic expression affected Bone morphogenetic protein expression (BMP2), an important bone anabolic agent that is also p53 regulated. Putative target binding sites for bone-specific transcription factors Runx2, SP7, Vitamin D receptor (VDR) were found for mIR34b and 140 and were utilized in luciferase reporter assays to confirm microRNA specific interactions. These studies provided evidence and confirmed for us that the p53 regulation of osteoblast differentiation is also mediated through specific microRNAs that directly target important bone-specific genes. Citation Format: Elisha Pendleton, Shivang Shah, Oliver Couture, Teresa Kusper, Mustafa Broachwalla, Lauren Alt, Michael Fay, Nalini Chandar. p53 regulation of osteoblast differentiation is mediated through specific microRNAs [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1796.
Loudness Recruitment
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Incorrect Spelling of an Author’s Name and Data Error
Authors: Brandon Kirsch, Brian Drolet
Journal: JAMA (2018)

Roger Stupp, MD; Sophie Taillibert, MD; Andrew Kanner, MD; William Read, MD; David M. Steinberg, PhD; Benoit Lhermitte, MD; Steven Toms, MD; Ahmed Idbaih, MD; Manmeet S. Ahluwalia, MD; Karen Fink, MD, PhD; Francesco Di Meco, MD; Frank Lieberman, MD; Jay-Jiguang Zhu, MD, PhD; Giuseppe Stragliotto, MD, PhD; David D. Tran, MD, PhD; Steven Brem, MD; Andreas F. Hottinger, MD, PhD; Eilon D. Kirson, MD, PhD; Gitit Lavy-Shahaf, PhD; Uri Weinberg, MD, PhD; Chae-Yong Kim, MD, PhD; Sun-Ha Paek, MD, PhD; Garth Nicholas, MD; Jordi Bruna, MD; Hal Hirte, MD; Michael Weller, MD; Yoram Palti, MD, PhD; Monika E. Hegi, PhD; Zvi Ram, MD
Problem of Vaccinal Complications After Oral Poliomyelitis Vaccination
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AGRANULOCYTIC ANGINA
Authors: BEATRICE R. LOVETT
Journal: JAMA (1924)

Within the last year, there have been reported in Germany<sup>1</sup>about a dozen cases of a most interesting condition, grave ulcerative angina associated with extreme leukopenia. This syndrome has been called agranulocytosis, or agranulocytic angina, and as far as reported the symptoms are remarkably similar in all instances. Women of middle age are affected, and the disease is fatal after a fairly acute course. The onset is sudden, with fever and sore throat. The characteristic lesions are rapidly spreading ulcers, invariably present on the tonsils and pharyngeal walls, often on the gums, larynx, tongue and about the genitalia. There is little or no enlargement of the regional lymph glands; in fact, there seems to be little reaction of any sort to the lesions, and no resistance to their rapid spread. Icterus, without obvious cause, occurs in a majority of the patients. A hemorrhagic diathesis is not usually part of
Moderne Therapie in innerer Medizin und Allgemeinpraxis.
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
British American Exchange Fellowships in Cancer Research
Journal: JNCI Journal of the National Cancer Institute (1950)

Journal Article British American Exchange Fellowships in Cancer Research Get access JNCI: Journal of the National Cancer Institute, Volume 11, Issue 1, August 1950, Pages 237–238, https://doi.org/10.1093/jnci/11.1.237 Published: 01 August 1950
Breast Diseases
Authors: Yeu-Tsu Margaret Lee
Journal: JAMA (1992)

The purpose of this book, as stated in the preface, is to provide the reader with current, comprehensive, scientifically valid, and easy-to-read information about breast disease. The book, with 69 contributors, has 26 chapters with many tables and illustrations. All four editors are recognized cancer specialists: two radiotherapists and one medical and one surgical oncologist. Excluding the first four chapters, which describe anatomy and various benign breast disorders, the book covers all aspects of breast cancer from the biology, diagnosis, and pathology to treatment of primary and metastatic diseases, patterns of failure (local and distant), special therapeutic problems, rehabilitation, and psychosocial support. This expanded second edition has a special feature, a "Management Summary," at the end of each clinical topic discussion. Written by the editors, it provides succinct and pertinent patient-care guidelines. Chapters by surgeons for primary therapy and aesthetic and reconstructive surgery have many clear illustrations, with preoperative and
Proceedings of The Thoracic Society
Journal: Thorax (1977)

Circulatingantibody to pigeon protein was measured sequentially during the recovery phase from acute pigeon breeder's disease in a group of seven patients using a radioimmunoassay technique (Nielsen et al., 1974).All were shown to have high levels initially which fell in an exponential manner when no further contact with pigeon protein occurred.This decay to a reduced level of response over a 2-4 month period differed from the responses noted in farmer's lung where the antibody levels to Micropolyspora faeni remained ele- vated for much longer periods.This reflected the soluble nature of the pigeon protein antigen com- pared with the particulate antigen of the organism responsible for farmer's lung.If, after resolution of an acute symptomatic episode, patients returned to their previous activities and ex- posure to pigeon protein persisted, the levels of circu- lating antibody remained elevated.The continued inhalation of antigen promoted the continued produc- tion of antibody which tended to be maintained at a fairly constant level in each individual.Once exposure ceased for a significant length of time, antibody pro- duction decreased sharply and fell to a new lower level which persisted for a much longer period and which reflected a new stable state of antibody production.Following challenge with antigen in one sensitised individual, circulating antibody fell by 30% within 30 minutes of the start of exposure, thus providing objective evidence for the utilisation of antibody during the acute phase of the condition and, therefore, the presence of an Arthus type reaction in the tissues.Thereafter, antibody levels increased slowly to a peak some three weeks later, indicating a secondary response following stimulation of antibody production similar to that seen after challenge with any other antigen.
Biochemistry of Protein-Isocyanate Interactions: A Comparison of the Effects of Aryl vs. Alkyl Isocyanates
Authors: William E. Brown, Allen H. Green, Thomas E. Cedel, Jennifer Cairns
Journal: Environmental Health Perspectives (1987)

In addition to their use in the polyurethane and pesticide industries, isocyanates have proven to be useful probes for the exploration of protein structure. This paper focuses on three aspects of isocyanates: their broad reactivity, their reversible interaction with cholinesterases, and the relative hydrolysis rates of alkyl and aryl isocyanates. The broad reactivity of isocyanates as well as the demonstrated affinity labeling of serine and sulfhydryl esterases are discussed. Extension of the affinity labeling studies to include the analysis of the inhibition of cholinesterases by methyl isocyanate shows that methyl isocyanate is not an effective inhibitor of any of the cholinesterases. The inhibition of cholinesterases by alkyl isocyanates shows a pattern of decreased specificity with decreased alkyl chain length. The inhibition of cholinesterases by isocyanates is shown to be reversible, with a maximum rate of reversal seen at physiological pH. This reversal is characteristic of the reaction of an isocyanate with a sulfhydryl group. Finally, the affinity labeling of proteins must compete successfully with the hydrolysis of isocyanates in aqueous solution. The hydrolysis of alkyl isocyanates is shown to be significantly slower than that of the aryl isocyanates.
Abstract 57: Costimulation Mediated T-cell Survival Excerbates Kawasaki Disease
Authors: Leon Parsaud, Yasmin Moolani, Trang T Duong, Andrew C Lau, Garrett T Keong, Long T Hoang, Tania H Watts, Martin L Hibberd, Rae S Yeung
Journal: Circulation (2015)

Introduction: Kawasaki Disease (KD) is a multi-system vasculitis leading to coronary artery damage. Previous work has shown that co-stimulatory signals can rescue a subset of superantigen (SAg) reactive T-cells from apoptosis and one of the major pathways responsible for delivery of this co-stimulatory signal is CD28 signaling on T-cells. Lactobacillus casei cell wall extract (LCWE) contains a SAg among its active ingredients, leading to induction of coronary arteritis in mice that closely resembles human KD. Methods: Flow cytometry was used to measure the expression of pro-survival molecules and markers of apoptosis. In vivo studies were performed with C57BL/6 mice (4-5 weeks) injected i.p. with either LCWE, or LCWE and anti-4-1BB or Isotype control antibody. Cardiac tissue isolated, processed, stained and scored as per protocol. Gene expression analysis in KD patients was performed using the Illumina HumanHT-12v4. Results: Despite the fact that SAg-activated T-cells undergo apoptosis and are deleted, T-cells persist and are central to ongoing inflammation in affected arteries. Stimulation of CD28 leads to upregulation of pro-survival molecules cFLIP and BCLxL and reduction of caspase 3-annexinV double positive cells (markers of apoptosis) after SAg-stimulation, as detected by flow cytometry. In animals co-injected with anti-4-1BB (co-stimulation agonist), the incidence of coronary arteritis was dramatically increased to 94% compared to 54% with LCWE alone. Analysis of gene expression profile from 171 children with KD show elevated levels of molecules specific to the CD28 signaling cascade through Grb2, and VAV1 leading to the upregulation of Rac1 and CDC42, together with upregulation of pro-survival molecules cFLIP, MCL1 and NAIP. Interestingly, increased expression of cell survival molecules was associated with IVIG failure, with statistically significant elevation of NAIP and CDC42 and a trend towards increased expression for cFLIP and MCL, in IVIG non-responders compared to responders. Conclusions: Enhanced co-stimulation contributes to T-cell survival after SAg-stimulation leading to persistent coronary artery inflammation and poor treatment response in KD.
Muscle involvement in systemic lupus erythematosus
Authors: G. C. Tsokos
Journal: JAMA (1981)

Of 228 patients with systemic lupus erythematosus (SLE) admitted to our inpatient service during a 6.5-year period, 18 (8%) had prominent muscle disease. In the majority of these patients, myositis occurred at the time of diagnosis of SLE. The creatine phosphokinase level was normal in all but one of these patients; however, the serum aldolase level was frequently elevated. All patients responded promptly to corticosteroid treatment. (<i>JAMA</i>1981;246:766-768)
Microspore and Microgametophyte Development in Relation to Biological Activity of Environmental Pollutants
Authors: Joseph P. Mascarenhas
Journal: Environmental Health Perspectives (1981)

The pattern of synthesis of nucleic acids and proteins in the development of the microspore and later during pollen germination and tube growth is discussed.In the pollen grain at the time of anthesis all the proteins that are required for germination and early tube growth are either already present, or if new proteins are synthesized, the messenger RNAs for their synthesis already exist in the ungerminated pollen grain.In addition, similar proteins are synthesized on new mRNAs during germination and pollen tube growth as are synthesized on premade mRNAs.The genetic program during at least the latter part of pollen maturation prior to anthesis is thus the same as that during pollen germination and tube growth.Accordingly, one cannot treat mature pollen with mutagens and expect to be able to score the pollen tubes for mutant proteins.Treatment with mutagenic compounds would have to be during pollen maturation in the anther, before the transcription for the proteins required during germination and pollen tube growth has occurred.Available evidence indicates that this is very early in pollen development, possibly soon after meiosis.The value of pollen tubes to monitor for chemicals that affect the intracellular motilitv systems of organisms is also discussed.Pollen can, in theory, be used to assay for effects of chemicals on cellular processes that are general to all plant systems.In addition, there are other processes that can be studied that are unique to pollen and are concerned with the fertilization process.In this paper certain aspects of the molecular biology of pollen development will be (liscusse(l.This information might be of value in diexvising experimental protocols for the use of pollen as a monitoring system for potentially toxic chemicals released into the environment.
A randomized, open label, multicenter phase 2 study to evaluate the efficacy of sorafenib in patients (pts) with advanced renal cell carcinoma (RCC) after radical resection of metastases: RESORT trial.
Authors: Giuseppe Procopio, Paolo Grassi, Francesco Cognetti, Michele Milella, Alessandra Mosca, Vincenzo Emanuele Chiuri, Cinzia Ortega, Rodolfo Passalacqua, Alessandra Bearz, Franco Morelli, Francesco Atzori, Rosanna Montone, Alessia Mennitto, Raffaele Ratta, Filippo G. De Braud, Elena Verzoni
Journal: Journal of Clinical Oncology (2016)

TPS4582 Background: Complete response with targeted agents in metastatic renal cell carcinoma (mRCC) is rarely achieved. Retrospective data seem to indicate that metastasectomy (Mtx) may improve survival in selected pts. The RESORT study was designed to evaluate whether Mtx followed by sorafenib may provide additional clinical benefit. Methods: Overall 132 mRCC pts undergoing complete Mtx will be randomized 1:1 to receive either sorafenib or best supportive care (BSC) for 52 weeks or until disease recurrence. Patients will be stratified by prognostic factors including: time from nephrectomy to Mtx, site of disease and number of lesions. Key inclusion criteria: maximum 3 metastatic lesions; complete removal of all metastatic lesions; no tumor cells seen microscopically (R0 resection); no more than three months from Mtx. The primary endpoint is recurrence-free survival (RFS), defined as the time from randomization to diagnosis of disease relapse or death. Secondary endpoints are: overall survival (OS) and safety. Exploratory endpoints: evaluation of vascular endothelial growth factors (VEGF) and fibroblast growth factor (FGF) levels. Evaluation of the association between baseline CTCs count and RFS. Sorafenib will be administered at the dose of 400 mg orally once daily for 21 days and then increased to 400 mg twice daily if the patient has not experienced grade 2 skin toxicity or any other grade 3 toxicities. Imaging assessments will be performed every 12 weeks. Statistical plan:Kaplan-Meier methods will be used for survival analyses and the log-rank test to compare sorafenib arm and BSC arm according to the stratification factors. The hazard ratio (HR) will be determined at the 95% confidence interval (CI). The hypothesis is to increase the RFS time from 12 months (BSC arm) to 18 months (sorafenib arm), corresponding to a 50% improvement. With a study power of 80% and a 1-sided error of 0.15, the estimated number of events required is 86. Forthy-four out of 132 pts have been enrolled. Clinical trial information: NCT01444807.
ESGE News and Upcoming Events March 2019
Journal: Endoscopy (2019)

Dedicated to endoscopy and committed to innovation, ESGE Days 2019 is your congress! The scientific committee has been working hard on your behalf to put together a comprehensive and innovative programme including live endoscopy demonstrations, state-of-the-art lectures, hands-on training and much more. Visit the ESGE Days 2019 website (www.esgedays.org) to register and learn more about what we have in store for you in Prague! We look forward to seeing you there!